{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.8","upperLimit":"19.8","value":"10.4"},{"groupId":"OG001","lowerLimit":"2.2","upperLimit":"16","value":"7.6"}]}],"title":"100 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.8","upperLimit":"19.8","value":"10.4"},{"groupId":"OG001","lowerLimit":"2.2","upperLimit":"16","value":"7.6"}]}],"title":"180 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.8","upperLimit":"19.8","value":"10.4"},{"groupId":"OG001","lowerLimit":"2.2","upperLimit":"16","value":"7.6"}]}],"title":"365 days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Grade 2: Clinically active CMV infection (e.g. symptoms, cytopenias) or CMV Viremia not decreasing by at least 2/3 of the baseline value after 2 weeks of therapy; Grade 3: CMV end-organ involvement (pneumonitis, enteritis, retinitis). A cumulative incidence will be computed along with a 90% CI. Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first).\n\nThe overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days, 180 days, and 365 days","title":"Cumulative Incidences of Viral Reactivations and Infections: Grade 2-3 CMV Reactivation or Infection","type":"SECONDARY","unitOfMeasure":"percentage of participants"}